Announcement no. 19/2007
To OMX the Nordic Exchange Copenhagen, July 6,
2007
Total share capital and total number of votes in Curalogic A/S
Under section 17(2) of Executive Order no. 226 of 15 March 2007 on the
disclosure requirements of issuers, we hereby announce that, as of today,
Curalogic A/S' share capital totals DKK 28,214,408 divided into 56,428,816
shares of DKK 0.50 corresponding to 56,428,816 voting rights.
Yours sincerely,
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO, Phone +45 33 11 41 01, mobile +45 26 25 04 22
Helle Busck Fensvig, EVP and CFO, Phone +45 33 11 41 01, mobile +45 20 70 55 37
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic
Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the
treatment of allergy. By combining the best of two worlds - the efficacy of
immunotherapy combined with the safety and patient convenience of symptomatic
treatments - Curalogic aims to develop a novel and user-friendly form of allergy
treatment, and make it the preferred type of allergy treatment among patients.
Curalogic has a broad and mature pipeline with a product for treatment of
ragweed allergy in Phase III, a product for treatment of grass allergy ready for
Phase III, a product for treatment of cat allergy in Phase II and a product for
treatment of house dust mite allergy preparing for clinical trials.
